Want to see GB:VLG full AI Analyst Report?
Top Page
Venture Life
(LSE:VLG)
Select Model
Select Model
Rating:71Outperform
Price Target:
77.00 p
â–²(16.67% Upside)
Action:Upgraded
Date:08/06/26
The score is driven primarily by improving profitability and a significantly de-risked balance sheet, which support financial resilience. Technicals are also supportive with price above major moving averages and positive MACD. Offsetting these positives are uneven execution signals—especially the swing to negative operating/free cash flow in 2025—and only moderate valuation support given the lack of dividend yield data.
Positive Factors
Improved Profitability
The return to positive EBIT and materially higher net income indicates stronger underlying earnings power. If maintained, improved profitability can support reinvestment, strengthen resilience, and provide greater flexibility to expand the branded healthcare portfolio.
Negative Factors
Negative Recent Cash Flow
The reversal to negative operating and free cash flow weakens confidence that reported earnings are converting consistently into cash. Persistent working-capital demands or one-off uses of cash could restrict investment capacity and reduce financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Improved Profitability
The return to positive EBIT and materially higher net income indicates stronger underlying earnings power. If maintained, improved profitability can support reinvestment, strengthen resilience, and provide greater flexibility to expand the branded healthcare portfolio.
Read all positive factors
Venture Life (VLG) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£82.13M
Dividend Yield0.1%
Average Volume (3M)123.11K
Price to Earnings (P/E)15.7
Beta (1Y)0.22
Revenue GrowthN/A
EPS GrowthN/A
CountryUK
Employees165
SectorConsumer Defensive
Sector Strength42
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.04
Shares Outstanding119,900,560
10 Day Avg. Volume102,102
30 Day Avg. Volume123,114
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.04
Price to Sales (P/S)2.40
P/FCF Ratio-273.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.07
Revenue Forecast (FY)£54.70M
Venture Life Business Overview & Revenue Model
Company Description
Established in Bracknell, UK, in 2005, Venture Life Group plc is an international developer and marketer of diverse health and personal care items. The company's portfolio spans oral care products, dietary supplements, medical devices, dermo-cosme...
How the Company Makes Money
Venture Life primarily makes money by selling consumer healthcare products under its own brands and, in some cases, via licensed or acquired brands. Revenue is generated when these products are sold to distributors, pharmacy/retail chains, and oth...
Venture Life Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
85
Very Positive
Cash Flow
55
Neutral
| Breakdown | Dec 2025 | Jun 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 35.17M | 26.59M | 51.41M | 43.98M | 32.76M |
| Gross Profit | 11.79M | 12.19M | 20.15M | 17.66M | 12.96M |
| EBITDA | 5.08M | 4.32M | 9.95M | 7.61M | 5.16M |
| Net Income | 6.13M | -314.00K | 921.00K | 520.00K | 2.40M |
Balance Sheet | |||||
| Total Assets | 99.18M | 124.49M | 119.50M | 125.29M | 103.63M |
| Cash, Cash Equivalents and Short-Term Investments | 34.17M | 3.05M | 5.62M | 5.63M | 5.24M |
| Total Debt | 667.00K | 23.86M | 24.39M | 26.85M | 12.73M |
| Total Liabilities | 17.76M | 49.08M | 43.24M | 49.63M | 30.47M |
| Stockholders Equity | 81.42M | 75.41M | 76.25M | 75.66M | 73.16M |
Cash Flow | |||||
| Free Cash Flow | -309.00K | 8.34M | 5.81M | 1.36M | -2.66M |
| Operating Cash Flow | -264.00K | 8.35M | 8.22M | 5.57M | 601.00K |
| Investing Cash Flow | 53.98M | -11.29M | -5.34M | -11.69M | -39.18M |
| Financing Cash Flow | -23.77M | 1.78M | -2.81M | 6.92M | 1.50M |
Venture Life Technical Analysis
Positive
66.00
Price Trends
67.62
Positive
64.48
Positive
65.48
Positive
Market Momentum
-0.11
Negative
65.84
Neutral
82.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VLG, the sentiment is Positive. The current price of 66 is below the 20-day moving average (MA) of 66.05, below the 50-day MA of 67.62, and above the 200-day MA of 65.48, indicating a bullish trend. The MACD of -0.11 indicates Negative momentum. The RSI at 65.84 is Neutral, neither overbought nor oversold. The STOCH value of 82.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:VLG.
Venture Life Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | £82.13M | 15.71 | 7.82% | 0.10% | ― | ― | |
66 Neutral | £29.36B | 18.40 | 9.89% | 2.19% | 1.21% | 8.33% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
45 Neutral | £24.63M | -105.00 | -49.45% | ― | -27.38% | -50.00% | |
45 Neutral | £49.86M | -6.43 | 64.57% | ― | 36.19% | 60.75% | |
41 Neutral | £300.80M | -4.80 | 409.00% | ― | 2.94% | -32.00% |
* Consumer Defensive Sector Average
GB:VLG
Venture Life
68.50
11.50
20.18%
GB:AGY
Allergy Therapeutics
4.75
-3.55
-42.77%
GB:PXS
Provexis
1.05
0.39
57.89%
GB:STX
Shield Therapeutics
4.66
-3.64
-43.86%
GB:HLN
Haleon PLC
333.80
-15.81
-4.52%
Venture Life Corporate Events
Regulatory Filings and Compliance
Venture Life Updates Share Capital and Voting Rights Structure
Neutral
Aug 3, 2026
Venture Life Group, a UK-based international consumer self-care specialist, develops and markets pharmacist-recommended products spanning women’s intimate health, ENT care, energy and glucose management, and hormonal lifecycle support. The c...
Stock BuybackRegulatory Filings and Compliance
Venture Life Adds to Treasury Stock in Ongoing Share Buyback
Positive
Aug 3, 2026
Venture Life Group has repurchased 35,000 ordinary shares at a volume-weighted average price of 69.70 pence as part of its ongoing share buyback programme, with the acquired shares to be held in treasury. Following this transaction, the company ha...
Stock BuybackRegulatory Filings and Compliance
Venture Life Adds to Treasury Stock in Latest Share Buyback
Positive
Jul 31, 2026
Venture Life Group plc has executed a further share repurchase under its ongoing buyback programme, acquiring 50,000 ordinary shares at a volume-weighted average price of 70 pence each through Cavendish Capital Markets. The purchased shares will b...
Business Operations and StrategyStock BuybackFinancial Disclosures
Venture Life Adds to Share Buyback, Updates Voting Rights
Positive
Jul 29, 2026
Venture Life Group PLC has executed a further tranche of its share buyback programme, purchasing 65,963 ordinary shares at a volume-weighted average price of 69.38 pence per share through Cavendish Capital Markets. The repurchased shares will be h...
Stock BuybackRegulatory Filings and Compliance
Venture Life adds treasury shares in ongoing buyback, updates voting rights
Neutral
Jul 28, 2026
Venture Life Group plc, a UK-headquartered consumer healthcare company specialising in proactive healthy longevity and self-care products, markets pharmacist-recommended brands such as Balance Activ, Earol and Health Her across global retail and ...
Business Operations and StrategyRegulatory Filings and Compliance
Venture Life Updates Share Capital After Employee Option Exercise
Neutral
Jul 27, 2026
Venture Life Group PLC, a UK-based consumer healthcare company specialising in self-care products such as Balance Activ, Earol, Lift, Glucogel and Health Her, distributes its portfolio through retail and e-commerce channels worldwide. Its offerin...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life Boosts Treasury Stock with New Share Buyback
Positive
Jul 27, 2026
Venture Life Group PLC has executed a further tranche of its previously announced share buyback programme, purchasing 46,716 ordinary shares at a volume-weighted average price of 69.30 pence, with the shares to be held in treasury. Following this ...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life Repurchases 200,000 Shares Under Ongoing Buyback Programme
Positive
Jul 24, 2026
Venture Life Group has repurchased 200,000 ordinary shares at a volume-weighted average price of 70.12 pence under its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction, the company has 128,860,145...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life adjusts treasury holdings and voting rights through share transfer and buyback
Neutral
Jul 22, 2026
Venture Life Group PLC has transferred 50,000 ordinary shares from treasury to satisfy options exercised by an employee under its share option scheme, while simultaneously maintaining balance through its ongoing capital management strategy. The mo...
Business Operations and StrategyStock Buyback
Venture Life Tightens Free Float with Further Treasury Share Buyback
Positive
Jul 22, 2026
Venture Life Group PLC, a specialist in consumer self-care and healthy longevity solutions, markets brands such as Balance Activ, Earol, Lift, Glucogel and Health Her across pharmacies, health and beauty chains, grocery retailers and online chann...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life Adds to Buyback, Updates Voting Rights
Positive
Jul 21, 2026
Venture Life Group PLC has executed a further tranche of its previously announced share buyback programme, purchasing 200,000 ordinary shares at a volume-weighted average price of 70.40 pence each through Cavendish Capital Markets. The shares acqu...
Stock BuybackRegulatory Filings and Compliance
Venture Life Buys Back 100,000 Shares, Updates Voting Rights
Positive
Jul 20, 2026
Venture Life Group PLC has executed a further tranche of its previously announced share buyback programme, purchasing 100,000 ordinary shares at a volume weighted average price of 69.60 pence through Cavendish Capital Markets. The acquired shares ...
Stock BuybackRegulatory Filings and Compliance
Venture Life Expands Treasury Stock with Latest Share Buyback
Positive
Jul 16, 2026
Venture Life Group plc, a UK-headquartered consumer self-care company specialising in proactive healthy longevity products across women’s health, ENT care, energy and glucose management, and hormonal support, distributes its brands through p...
Business Operations and StrategyRegulatory Filings and Compliance
Venture Life Transfers Treasury Shares to Settle Employee Options
Neutral
Jul 14, 2026
Venture Life Group PLC, a UK-based leader in consumer healthcare product innovation and commercialisation, operates globally with a diversified portfolio including Balance Activ, Earol, Lift, Glucogel and Health Her. Its self-care products target...
Business Operations and StrategyRegulatory Filings and Compliance
Venture Life Updates Share Capital After Employee Option Exercises
Neutral
Jul 13, 2026
Venture Life Group PLC has transferred 257,500 ordinary shares from treasury to satisfy options exercised under its employee share option scheme, reflecting ongoing use of equity-based incentives for staff. Following this move, the total number of...
Stock BuybackRegulatory Filings and Compliance
Venture Life Adds to Treasury Stock with Latest Share Buyback
Positive
Jul 10, 2026
Venture Life Group plc, a UK-headquartered consumer self-care specialist in proactive healthy longevity, supplies pharmacist-recommended products like Balance Activ, Earol, Lift, Glucogel and Health Her across global retail and online channels. I...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life Repurchases Shares Under Ongoing Buyback Programme
Positive
Jul 9, 2026
Venture Life Group plc has repurchased 173,978 ordinary shares at a volume-weighted average price of 66.50 pence per share under its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction, the company h...
Business Operations and StrategyRegulatory Filings and Compliance
Venture Life Updates Total Voting Rights and Share Capital Structure
Neutral
Jul 2, 2026
Venture Life Group PLC, a UK-headquartered international consumer self-care company, markets a range of over-the-counter health products spanning women’s intimate care, ENT support, energy and glucose management and hormonal lifecycle suppor...
Regulatory Filings and Compliance
Venture Life Chairman Increases Stake with Share Purchase
Positive
Jun 30, 2026
Venture Life Group PLC reported that Non-Executive Chairman Paul McGreevy has acquired 93,887 ordinary shares in the company at a volume-weighted average price of 63.9 pence per share on 30 June 2026. Following this transaction, McGreevy’s b...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Venture Life Powers Double-Digit Growth With Brand Investment and AI-Led Transformation
Positive
Jun 30, 2026
Venture Life reported revenues of £50.0 million for the seventeen months to 31 May 2026, up 30.9% on the prior period, with pro forma growth of 16.0% driven largely by higher volumes and Power Brands now accounting for more than 90% of sales....
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life Tightens Capital Base with Treasury Share Buyback
Positive
Jun 24, 2026
Venture Life Group has repurchased 40,578 ordinary shares at a volume-weighted average price of 66 pence under its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction, the company has 128,860,145 ord...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life Tightens Free Float with New Share Buyback
Positive
Jun 23, 2026
Venture Life Group has continued its ongoing share buyback programme by purchasing 77,033 ordinary shares at a volume-weighted average price of 66.20 pence per share, with the shares to be held in treasury. Following this transaction, the company ...
Stock BuybackRegulatory Filings and Compliance
Venture Life Adds to Treasury Stock in Ongoing Share Buyback
Neutral
Jun 22, 2026
Venture Life Group plc, a UK-headquartered consumer self-care specialist with a portfolio spanning women’s intimate healthcare, ENT care and energy and glucose management, continues to expand its presence in global retail and e-commerce chan...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life Tightens Free Float with Treasury Share Buyback
Positive
Jun 19, 2026
Venture Life Group has repurchased 90,029 ordinary shares at a volume-weighted average price of 66.09 pence per share under its existing share buyback programme, with all acquired shares to be held in treasury. Following this transaction, the comp...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Venture Life Tightens Capital Base with Treasury Share Buyback
Positive
Jun 18, 2026
Venture Life Group has repurchased 27,087 ordinary shares at a volume-weighted average price of 66.25 pence as part of its ongoing share buyback programme, with the acquired stock to be held in treasury. Following this transaction, the company has...
Business Operations and StrategyStock Buyback
Venture Life tightens share base with latest buyback
Positive
Jun 12, 2026
Venture Life Group has continued executing its share buyback programme by purchasing 58,622 ordinary shares at a volume-weighted average price of 66.15 pence, with the shares to be held in treasury. Following this transaction, the company has 128,...
Stock BuybackRegulatory Filings and Compliance
Venture Life Tightens Free Float with Latest Share Buyback
Positive
Jun 11, 2026
Venture Life Group PLC has repurchased 199,148 ordinary shares at a volume-weighted average price of 68 pence per share under its ongoing share buyback programme, with the shares to be held in treasury. Following this transaction, the company has ...
Other
Venture Life Chair Increases Stake with Fresh Share Purchase
Positive
Jun 4, 2026
Venture Life Group, an international consumer self-care specialist, develops and commercialises over-the-counter products in women’s health, ENT care, energy and glucose management, and hormonal health. Based in the UK, it sells primarily th...
Business Operations and StrategyFinancial DisclosuresM&A Transactions
Venture Life buys FemiClear and CUROXEN in $28m push into U.S. feminine health
Positive
Jun 3, 2026
Venture Life Group has agreed to acquire U.S. brands FemiClear and CUROXEN from OrganiCare Nature’s Sciences for up to $28m, funded entirely from existing cash resources. The deal gives Venture Life immediate scale in the U.S. feminine treat...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.